Stocks
Kyverna Therapeutics, Inc.KYTX
NASDAQHealthcareBiotechnology$5.39
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing engineered cell therapies for autoimmune diseases, with its lead candidate targeting CAR T-cell treatments for conditions like lupus and multiple sclerosis. Investors track Kyverna for its progress in applying CAR T technology beyond oncology, a frontier that could expand the addressable market for cell therapies.
52W Range: $5.36-$13.67
Congressional Interest in Kyverna Therapeutics, Inc. (KYTX)
No congressional trades have been disclosed for Kyverna Therapeutics, Inc. (KYTX) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading KYTX?
No congressional trades found for this stock.